Industry Voices—Few healthcare organizations fully understand the impact of new lease accounting standards

Hospitals cost
Under a new accounting standard, operating leases longer than 12 months will be recorded as assets and liabilities on the balance sheet. (Getty/ronstik)

Few healthcare organizations fully understand the impact a new lease accounting standard, which takes effect next year, could have on their bottom line—even though the change was announced two years ago.

The new lease accounting standard change—Accounting Standards Codification (ASC) 842—was issued by the Financial Accounting Standards Board in February 2016. Until now, operating leases have not been accounted for on organizations’ balance sheets.

RELATED: To buy or lease equipment? Depends on the hospital


13th Partnering with ACOS & IDNS Summit

This two-day summit taking place on June 10–11, 2019, offers a unique opportunity to have invaluable face-to-face time with key executives from various ACOs and IDNs from the entire nation – totaling over 3.5 million patients served in 2018. Exclusively at this summit, attendees are provided with inside information and data from case studies on how to structure an ACO/IDN pitch, allowing them to gain the tools to position their organization as a “strategic partner” to ACOs and IDNs, rather than a merely a “vendor.”

But under ASC 842, operating leases longer than 12 months will be recorded as assets and liabilities on the balance sheet.    

It’s a change that could significantly impact financial covenant calculations by healthcare organizations under their borrowing agreements. It could also affect the structure of future borrowing agreements and their choice of financing product.

Kevin Gore, a partner with BKD, LLP, said that based on discussions his accounting firm has had with clients, very few healthcare organizations have reviewed their borrowing documents to determine the potential impact on financial covenant calculations.

RELATED: Revenue recognition rule changes could create 'breeding ground' for healthcare fraud

The new lease accounting standard goes into effect in fiscal years starting after Dec. 15, 2018, for not-for-profit healthcare organizations and public companies that have debt, whether publicly issued or privately placed. For all other organizations, the new standard must be implemented in fiscal years beginning after Dec. 15, 2019. Organizations may choose early adoption.

To prepare, key actions healthcare leaders can take include:

  • Talk with lenders about their interpretation of the new lease accounting standard. It’s important to understand whether recording operating leases on the balance sheet will trigger financial covenant defaults for healthcare organizations under their existing borrowing agreements. If amendments to existing borrowing agreements are needed, consult with your financial adviser and bond counsel regarding the best way to proceed.
  • Make sure all new borrowing agreements feature language that excludes operating leases from the definition of debt. Borrowing agreements also should include language that clarifies that operating leases will not be considered when calculating financial ratios.  
  • Complete a financial statement impact analysis before making lease-vs.-buy decisions. Work with your financial adviser to evaluate all lease-vs.-buy decisions and the structure of all leases in light of the new lease accounting standard.  

While the impact of the new lease accounting standard will vary by organization, healthcare leaders can implement these strategies now to mitigate their risk.

Jay Miele is a managing director of H2C, based in San Diego, California. Jenna Magan is a partner at Orrick, based in Sacramento, California.

Suggested Articles

The FTC is suing Surescripts, accusing the health IT company of employing illegal restraints to maintain its monopolies over the e-prescribing market.

Group plans for small businesses may offer a lower-cost option in comparison to individual market coverage, according to a new report. 

Ohio’s attorney general is continuing his war on PBMs, this time by proposing a multi-step plan to improve transparency and lower drug costs.